Company intelligence / Profile preview

Inspiration Biopharmaceuticals

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Inspiration Biopharmaceuticals filed for Chapter 11 bankruptcy protection[1]. The company's lead product IB1001 (recombinant factor IX for hemophilia B) had marketing applications under review by the FDA and EMA[1]. OBI-1 (recombinant porcine factor VIII) had pivotal clinical trials underway with the acquired hemophilia trial approaching enrollment completion[1].

Therapeutic areas: Hematology
Modalities: Recombinant protein
Industry: Biotech

Partnerships

Ipsen

Beyond the preview

Go deeper on Inspiration Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inspiration Biopharmaceuticals.

Explore the full profile